Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases

J Autoimmun. 2023 Jul:138:103051. doi: 10.1016/j.jaut.2023.103051. Epub 2023 May 22.

Abstract

Tolerogenic dendritic cells play a critical role in promoting antigen-specific tolerance via dampening of T cell responses, induction of pathogenic T cell exhaustion and antigen-specific regulatory T cells. Here we efficiently generate tolerogenic dendritic cells by genetic engineering of monocytes with lentiviral vectors co-encoding for immunodominant antigen-derived peptides and IL-10. These transduced dendritic cells (designated DCIL-10/Ag) secrete IL-10 and efficiently downregulate antigen-specific CD4+ and CD8+ T cell responses from healthy subjects and celiac disease patients in vitro. In addition, DCIL-10/Ag induce antigen-specific CD49b+LAG-3+ T cells, which display the T regulatory type 1 (Tr1) cell gene signature. Administration of DCIL-10/Ag resulted in the induction of antigen-specific Tr1 cells in chimeric transplanted mice and the prevention of type 1 diabetes in pre-clinical disease models. Subsequent transfer of these antigen-specific T cells completely prevented type 1 diabetes development. Collectively these data indicate that DCIL-10/Ag represent a platform to induce stable antigen-specific tolerance to control T-cell mediated diseases.

Keywords: Celiac disease; Dendritic cells; IL-10; Immune tolerance; Tr1 cells; Type 1 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens
  • Celiac Disease
  • Dendritic Cells / metabolism
  • Diabetes Mellitus, Type 1* / metabolism
  • Diabetes Mellitus, Type 1* / therapy
  • Humans
  • Immune Tolerance
  • Interleukin-10* / genetics
  • Interleukin-10* / metabolism
  • Mice
  • T-Lymphocytes, Regulatory / metabolism

Substances

  • Antigens
  • Interleukin-10